Aytu Biopharma (AYTU) Cost of Revenue (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Cost of Revenue data on file, last reported at $4.8 million in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 14.77% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $19.9 million, a 3.77% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 27.42% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.8 million, down from $5.5 million in the prior quarter.
• Over the last five years, Cost of Revenue for AYTU reached as high as $12.6 million in Q2 2022 and fell as low as $3.5 million in Q2 2024.
• Historically, Cost of Revenue has averaged $6.9 million across 5 years, with a median of $5.4 million in 2024.
• Across the five-year window, Cost of Revenue slumped 70.9% in 2024 and soared 54.09% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $9.0 million in 2022, then plunged by 53.87% to $4.1 million in 2023, then surged by 31.12% to $5.4 million in 2024, then grew by 1.95% to $5.5 million in 2025, then dropped by 13.16% to $4.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $4.8 million in Q1 2026, $5.5 million in Q4 2025, and $4.7 million in Q3 2025.